**SUPPLEMENTARY TEXT AND TABLE S6: RESULTS FOR ADVERSE EVENTS**

In total 174 adverse events occurred involving 73 (61.3%) patients (38 or 63.3 % in the control and 35 or 59.3% in the TERECO group). Of the events 78 were recorded in the control and 96 in the TERECO group. 64 events occurred during the intervention period (19 in controls and 45 in the TERECO group). All but one of those events (stomach ulcers of one patient in the control group were rated as moderately severe) were classified as very mild to moderate. These events mostly comprised uncomfortable symptoms including chest tightness, feelings of weakness or reduced physical strength, and cough. See Table S6.1 for details.

.

**Table S6.1: Distribution of adverse events across study period and comparison groups**

| | Whole study period | | | During intervention period | | | During follow up period | | |
|---|---|---|---|---|---|---|---|---|---|
| | Total (n= 119) | Control (n=60) | TERECO (n=59) | Total (n= 119) | Control (n=60) | TERECO (n=59) | Total (n= 105) | Control (n=55) | TERECO (n=50) |
| **Per study participant** | | | | | | | | | |
| *Occurrence of any event, n(percent)* | | | | | | | | | |
| no | 46 (38.66) | 22 (36.67) | 24 (40.68) | 85 (71.43) | 51 (85.00) | 34 (57.63) | 45 (42.86) | 19 (34.55) | 26 (52.00) |
| yes | 73 (61.34) | 38 (63.33) | 35 (59.32) | 34 (28.57) | 9 (15.00) | 25 (42.37) | 60 (57.14) | 36 (65.45) | 24 (48.00) |
| *Number if occurred, n(percent)* | | | | | | | | | |
| 1 event | 29 (39.73) | 18 (47.37) | 11 (31.43) | 14 (41.18) | 2 (22.22) | 12 (48.00) | 31 (51.67) | 20 (55.56) | 11 (45.83) |
| 2 events | 20 (27.40) | 11 (28.95) | 9 (25.71) | 13 (38.24) | 5 (55.56) | 8 (32.00) | 18 (30) | 12 (33.33) | 6 (25.00) |
| 3 events | 9 (12.33) | 3 (7.89) | 6 (17.14) | 4 (11.76) | 1 (11.11) | 3 (12.00) | 5 (8.33) | 1 (2.78) | 4 (16.67) |
| more than 3 events | 15 (20.55) | 6 (15.79) | 9 (25.71) | 3 (8.82) | 1 (11.11) | 2 (8.00) | 6 (10) | 3 (8.33) | 3 (12.50) |
| *Hospitalized, n(percent)* | | | | | | | | | |
| no | 111 (94.12) | 57(95.00) | 54 (91.53) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 97 (92.38) | 57(94.55) | 45 (90.00) |
| yes | 8 (6.72) | 3 (5.00) | 5 (8.47) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (7.62) | 3 (5.45) | 5 (10.00) |
| | | | | | | | | | |
| **Per event** | | | | | | | | | |
| *Total number of events* | 174 | 78 | 96 | 64 | 19 | 45 | 110 | 59 | 51 |
| *Severity, n(percent)*[§] | | | | | | | | | |
| very mild, no follow up | 21 (12.07) | 8 (10.26) | 13 (13.54) | 12 (18.75) | 2 (10.53) | 10 (22.22) | 9 (8.18) | 6 (10.17) | 3 (5.88) |
| mild, further observation | 122 (70.11) | 61 (78.21) | 61 (63.54) | 34 (53.13) | 13 (68.42) | 21 (46.67) | 88 (80) | 48 (81.36) | 40 (78.43) |
| moderate, needs medical attention | 24 (13.79) | 4 (5.13) | 20 (20.83) | 17 (26.56) | 3 (15.79) | 14 (31.11) | 7 (6.36) | 1 (1.69) | 6 (11.76) |
| moderate to severe, needs treatment | 7 (4.02) | 5 (6.41) | 2 (2.08) | 1 (1.56) | 1 (5.26) | 0 (0) | 6 (5.45) | 4 (6.78) | 2 (3.92) |
| *Relationship with intervention,* | | | | | | | | | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| *n(percent)*[§] | | | | | | | | | |
| unlikely | 117 (67.24) | 62 (79.49) | 55 (57.29) | 10 (15.63) | 5 (26.32) | 5 (11.11) | 107 (97.27) | 57 (96.61) | 50 (98.04) |
| possible | 29 (16.67) | 10 (12.82) | 19 (19.79) | 27 (42.19) | 8 (42.11) | 19 (42.22) | 2 (1.82) | 2 (3.39) | 0 (0.00) |
| likely | 28 (16.09) | 6 (7.69) | 22 (22.92) | 27 (42.19) | 6 (31.58) | 21 (46.67) | 1 (0.91) | 0 (0.00) | 1 (1.96) |
| *Types of adverse events*[‡]*, n(percent)* | | | | | | | | | |
| chest tightness | 36 (20.69) | 13 (16.67) | 23 (23.96) | 10 (15.63) | 0 (0.00) | 10 (22.22) | 26 (23.64) | 13 (22.03) | 13 (25.49) |
| weakness | 18 (10.34) | 12 (15.38) | 6 (6.25) | 3 (4.69) | 2 (10.53) | 1 (2.22) | 15 (13.64) | 10 (16.95) | 5 (9.80) |
| cough | 14 (8.05) | 8 (10.26) | 6 (6.25) | 1 (1.56) | 0 (0.00) | 1 (2.22) | 13 (11.82) | 8 (13.56) | 5 (9.80) |
| reduced physical strength | 12 (6.9) | 6 (7.69) | 6 (6.25) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 12 (10.91) | 6 (10.17) | 6 (11.76) |
| sputum discharge | 10 (5.75) | 5 (6.41) | 5 (5.21) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 10 (9.09) | 5 (8.47) | 5 (9.80) |
| dizziness | 7 (4.02) | 1 (1.28) | 6 (6.25) | 7 (10.94) | 1 (5.26) | 6 (13.33) | 0 (.000) | 0 (0.00) | 0 (0.00) |
| chest pain | 6 (3.45) | 1 (1.28) | 5 (5.21) | 5 (7.81) | 0 (0.00) | 5 (11.11) | 1 (0.91) | 1 (1.69) | 0 (0.00) |
| back pain | 6 (3.45) | 3 (3.85) | 3 (3.13) | 5 (7.81) | 2 (10.53) | 3 (6.67) | 1 (0.91) | 1 (1.69) | 0 (0.00) |
| other | 65 (37.36) | 29 (37.18) | 36 (37.5) | 33 (51.56) | 14 (73.68) | 19 (42.22) | 32 (29.09) | 15 (25.42) | 17 (33.33) |

[§] Rated by two doctors who had access to event history and medical history of each patient but were blinded to group allocation. Doctors were not otherwise involved in the study. Ratings were compared after a first round of independent rating (average ICC = 0.63 for severity ratings and 0.82 for relationship with intervention). Disagreement on particular events was resolved by discussion and consensus. If consensus could not be achieved a third doctor was consulted who had the casting vote. [‡] Listed are all adverse events with occurrence ≥ 5 events, all other events are subsumed under "other".